Scholar Rock Holding (SRRK) Shares Outstanding (Diluted Average) (2020 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Shares Outstanding (Diluted Average) of $127.3 million in Q1 2026, up 10.96% quarter-over-quarter from $114.7 million in Q4 2025, and up 13.8% on a YoY basis from $111.8 million in Q1 2025.
Scholar Rock Holding (SRRK) Shares Outstanding (Diluted Average) (2020 - 2026) Analysis & Trends
Scholar Rock Holding's Shares Outstanding (Diluted Average) history runs 7 years deep, the most recent figure standing at $127.3 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 13.8% year-over-year to $127.3 million; the TTM figure through Mar 2026 stood at $127.3 million (up 13.8% YoY), while the FY2025 annual figure was $114.7 million, up 14.89% from the prior year.
- Shares Outstanding (Diluted Average) was $127.3 million for Q1 2026 at Scholar Rock Holding, up from $114.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $127.3 million in Q1 2026 to a low of $37.5 million in Q1 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $87.1 million across 5 years, with a median of $95.9 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Diluted Average) gained 2.96% in 2022, then soared 112.54% in 2023.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $59.6 million in 2022, then surged by 39.82% to $83.3 million in 2023, then advanced by 19.79% to $99.8 million in 2024, then advanced by 14.89% to $114.7 million in 2025, then gained by 10.96% to $127.3 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $127.3 million (Q1 2026), $114.7 million (Q4 2025), and $112.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | 127.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 127.28 Mn |
| Dec 31, 2025 | 114.70 Mn |
| Sep 30, 2025 | 112.76 Mn |
| Jun 30, 2025 | 112.27 Mn |
| Mar 31, 2025 | 111.84 Mn |
| Dec 31, 2024 | 99.84 Mn |
| Sep 30, 2024 | 96.59 Mn |
| Jun 30, 2024 | 96.81 Mn |
| Mar 31, 2024 | 95.89 Mn |
| Dec 31, 2023 | 83.35 Mn |
| Sep 30, 2023 | 80.12 Mn |
| Jun 30, 2023 | 79.87 Mn |
| Mar 31, 2023 | 79.61 Mn |
| Dec 31, 2022 | 59.61 Mn |
| Sep 30, 2022 | 52.96 Mn |
| Jun 30, 2022 | 39.55 Mn |
| Mar 31, 2022 | 37.46 Mn |
| Dec 31, 2021 | 36.71 Mn |
| Sep 30, 2021 | 36.55 Mn |
| Jun 30, 2021 | 36.48 Mn |